Search results for "Estro."

Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies

2016

International audience; Over the past few years, several studies have focused attention on the impact of breast cancer (BC) histological subtype or BC phenotype, as defined by hormone receptors (HR) and HER2 status, on the results of FDG-PET/CT at staging, or during neoadjuvant chemotherapy (NAC). At staging, sclerotic bone metastases from invasive lobular carcinoma (ILC) demonstrated low or no FDG uptake in comparison to metastases from invasive ductal carcinoma (IDC). The CT component of PET/CT imaging should be carefully analyzed in the staging of ILC. In patients with triple negative or HER2-positive tumors, the proportion of extraskeletal metastases is high; this must be taken into acc…

Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer

1993

Immunohistochemistry of Estrogen Receptor (ER) and Progesterone Receptor (PR) has been performed in 687 cases of human breast cancer. The staining results have been compared by (1) computer-assisted image analysis (QIC Score) and (2) subjective grading of the cryostat sections ("German" IRS). Tumors without or with only weak ER or PR content may be distinguished by both methods from tumors with a high receptor content. The QIC Score values belonging to the intermediate IRS grades are distributed over a wide range, but no negative cases were found in these categories. It is concluded from our results that subjective grading of the slides is a simple, rapid and useful method for the determina…

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status

2015

International audience; We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Data on women suffering from de novo MBC and diagnosed from 1998 to 2009 were provided by the Côte-d'Or breast cancer registry. NS was described using the Pohar Perme estimator and prognostic factors were investigated in a generalised linear model. We identified 232 patients (mean age = 64.7). Median NS was 29.2 months, 1- and 5-year NS were 76% and 26% respectively. The survival trend in patients with HER2-positive tumours who did not …

Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA).

1993

Estrogen content and metabolism in human breast tumor tissues and cells.

1996

Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Gr…

2021

Many cancer patients use integrative therapies with a combination of natural products and diets. In the Western world, integrative medicine is often not shared with oncologists even during antineoplastic treatments. This behavior stems from the unmet needs of cancer patients who may feel oncologists’ underestimation of their symptoms and spiritual aspects. This case report demonstrates the potential harm of inadequate diet and nutraceutical intake in a 68-year-old woman with metastatic estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer. Her care team recommended hormone therapy with abemaciclib plus fulvestrant. Her diarrhea started after 10 days of …

HER2-positive male breast cancer: an update.

2010

Laura Ottini1, Carlo Capalbo2, Piera Rizzolo1, Valentina Silvestri1, Giuseppe Bronte3, Sergio Rizzo3, Antonio Russo31Department of Experimental Medicine, “Sapienza” University of Rome, Rome, Italy; 2Medical Oncology, IDI-IRCCS, Rome, Italy; 3Department of Surgical and Oncological Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyAbstract: Although rare, male breast cancer (MBC) remains a substantial cause for morbidity and mortality in men. Based on age frequency distribution, age-specific incidence rate pattern, and prognostic factor profiles, MBC is considered similar to postmenopausal breast cancer (BC). Compared with female BC (FBC), MBC cas…

From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters

2006

Recently, chemoprevention trials have demonstrated the efficacy of preventive medical treatment (PMT) in reducing breast cancer (BC) detection rates in at-risk affected and unaffected women selected according to clinical and/or familial risk criteria, particularly with the use of tamoxifen (TAM). Major concerns limiting the routine use of TAM are the questionable benefit/risk ratio and poor patient compliance, which justify the studies undertaken to determine the efficacy of aromatase inhibitors (AIs) with respect to TAM. Issues such as therapy duration, impact on survival, incidence of side-effects and which subsets benefit most from treatment, still remain unsolved. Therefore, only ER+ BC…

Evaluación del grado de conversión de los receptores HER2, RE y RPg entre el cáncer de mama primario y sus respectivas metástasis

2017

Introducción: Tradicionalmente, las decisiones terapéuticas tanto del cáncer de mama precoz como de los estadios avanzados se han basado en los marcadores predictivos del tumor primario, tales como el receptor de estrógeno (RE), el receptor de progesterona (RPg) y el receptor 2 del factor de crecimiento epidérmico humano (HER2), asumiendo que éstos permanecían inmutables a nivel de la recaída metastásica. Objetivos: El objetivo general de esta tesis era investigar si el estado de los receptores HER2, RE y RPg realmente puede cambiar durante la progresión del cáncer de mama y profundizar en las causas y en el impacto clínico de dichos cambios. El objetivo principal era determinar la tasa de …

Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.

2003

Objective To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT) on serum homocysteine levels in postmenopausal women. Design An open, prospective, controlled study. Seventy-five healthy postmenopausal women were recruited as eligible for the study. Fifty women seeking HRT were randomized to receive continuous 17beta-estradiol, either by oral (2 mg daily; n = 25) or transdermal (50 microg daily; n = 25) administration, plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle. Twenty-five women unwilling to receive hormone treatment received only calcium supplementation, representing the control group. Fasting blood samples were analyzed at baselin…